BofA Securities Warns of 5% to 10% Sell-Off: 5 Safe Dividend Stocks to Buy Now24/7 Wall Street • 02/12/21
Molecular Templates Shares Jump On Research Pact With Bristol-Myers In Cancer SettingsBenzinga • 02/11/21
Biogen's Vumerity and Bristol Myers Squibb's Zeposia Show Signs of Early First-Line Success Among Multiple Sclerosis Patients Due to Tolerability and Onboarding Advantages Over Established AgentsPRNewsWire • 02/11/21
Opdivo Plus Cabometyx Combo Shows Superior Clinical Benefit Versus Sunitinib In Late-Stage Kidney Cancer StudyBenzinga • 02/09/21
Adjuvant Treatment with Opdivo (nivolumab) Demonstrates Statistically Significant and Clinically Meaningful Improvement in Disease-Free Survival in Patients with Muscle-Invasive Urothelial Carcinoma in Phase 3 CheckMate -274 TrialBusiness Wire • 02/08/21
OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Sustained Survival and Response Rate Benefits as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma in the Phase 3 CheckMate -9ER TrialBusiness Wire • 02/08/21
Bristol Myers Squibb Receives European Commission Approval for Inrebic® (fedratinib) for Adult Patients with Newly Diagnosed and Previously Treated MyelofibrosisBusiness Wire • 02/08/21
U.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel), a New CAR T Cell Therapy for Adults with Relapsed or Refractory Large B-cell LymphomaBusiness Wire • 02/05/21
Bristol Myers Squibb to Participate in Guggenheim's Virtual Healthcare Talks | 2021 Oncology DayBusiness Wire • 02/05/21
Bristol-Myers Squibb Co (BMY) CEO Giovanni Caforio on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/04/21
